Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates
暂无分享,去创建一个
[1] D. Greenblatt,et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. , 2001, The Journal of pharmacology and experimental therapeutics.
[2] M. Manns,et al. Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.
[3] S. Ludtke,et al. Mechanism of alamethicin insertion into lipid bilayers. , 1996, Biophysical journal.
[4] A. D. Rodrigues,et al. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[5] A. Boobis,et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.
[6] Rodrigues Ad,et al. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997 .
[7] A. Parkinson. An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.
[8] W. Trager,et al. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[9] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[10] Tony K L Kiang,et al. UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.
[11] A. D. Rodrigues,et al. Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.
[12] David J Greenblatt,et al. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[13] S. Wrighton,et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.
[14] E. Tanaka,et al. Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.
[15] F. Gonzalez,et al. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[16] C. Guillemette,et al. The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[17] D. Mansuy,et al. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.
[18] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[19] C. Adithan,et al. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. , 2007, Current clinical pharmacology.
[20] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[21] K. Krausz,et al. Monoclonal Antibodies and Multifunctional Cytochrome P450: Drug Metabolism as Paradigm , 2006, Journal of clinical pharmacology.
[22] B. Wong,et al. Complexities of glucuronidation affecting in vitro in vivo extrapolation. , 2002, Current drug metabolism.
[23] S. Clarke,et al. Characterization of the inhibition of P4501A2 by furafylline. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[24] Y. Berger,et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[25] A. Y. Lu,et al. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[26] D. Williams,et al. Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[27] J. Leonard,et al. Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers , 1998, Antimicrobial Agents and Chemotherapy.
[28] C. Guillemette. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes , 2003, The Pharmacogenomics Journal.
[29] S. Wrighton,et al. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[30] L. Richert,et al. Optimal detergent activation of rat liver microsomal UDP-glucuronosyl transferases toward morphine and 1-naphthol: contribution to induction and latency studies. , 1992, Biochemical pharmacology.
[31] A. Hsu,et al. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.
[32] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[33] R. Obach,et al. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[34] P. Lehman,et al. Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. Activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[35] J. Mandl,et al. Evidence for the intraluminal positioning of p-nitrophenol UDP-glucuronosyltransferase activity in rat liver microsomal vesicles. , 1994, Archives of biochemistry and biophysics.
[36] C. Jamis-Dow,et al. Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid , 1998, Antimicrobial Agents and Chemotherapy.
[37] S. Yamada,et al. Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms. , 2006, Drug metabolism and pharmacokinetics.
[38] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[39] H. Yamazaki,et al. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[40] G. de Sousa,et al. In vitro interaction between cyclosporin A and macrolide antibiotics. , 1993, British journal of clinical pharmacology.
[41] F. Schmidt. Meta-Analysis , 2008 .
[42] A. D. Rodrigues,et al. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.
[43] Rodrigues Ad,et al. Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .
[44] S. Higuchi,et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. , 1998, Therapeutic drug monitoring.
[45] R. Branch,et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.
[46] A. Rettie,et al. Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression , 2002, Pediatric Research.
[47] A. D. Rodrigues,et al. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. , 2002, Current drug metabolism.